<DOC>
	<DOCNO>NCT01440803</DOCNO>
	<brief_summary>Idiopathic osteoporosis ( IOP ) define osteoporosis affect young , otherwise completely healthy individual secondary cause bone loss . In course prior research premenopausal woman IOP , investigator show woman IOP low areal bone mineral density ( aBMD ) spine , hip forearm compare normal woman . Additionally , use noninvasive high resolution image central peripheral skeleton detail analysis transiliac crest bone biopsy , investigator identify several feature bone quality premenopausal woman IOP . There currently FDA-approved therapy IOP premenopausal woman . However , teriparatide ( Forteo ) show improve bone mass microarchitecture postmenopausal woman approve men primary idiopathic osteoporosis , well men , premenopausal postmenopausal woman glucocorticoid-induced osteoporosis . Because IOP premenopausal woman orphan disease , estimate prevalence 113,000 United States , pharmaceutical company unlikely support development therapy indication . Therefore , major objective protocol establish safety efficacy teriparatide premenopausal woman IOP phase 2 clinical trial . All subject receive teriparatide part study , randomly select group patient ( 10 ) receive one year placebo injection first start two year treatment . The remainder subject ( 30 ) receive active drug two year . Funding Source - FDA OOPD</brief_summary>
	<brief_title>Forteo Trial Idiopathic Osteoporosis Premenopausal Women</brief_title>
	<detailed_description>Osteoporosis skeletal disorder characterize reduce bone strength predisposes increase risk fracture . Osteoporosis affect postmenopausal woman elderly men unusual healthy individual age 50 . Moreover , 90 % young men premenopausal woman osteoporosis secondary cause bone lose , underlie disorder ( e.g. , hypogonadism ) medication exposure ( e.g. , glucocorticoid , antiepileptic drug ) , either interfered acquisition peak bone mass cause excessive bone loss thereafter . Idiopathic osteoporosis ( IOP ) define osteoporosis affect young , otherwise completely healthy individual intact gonadal function secondary cause bone loss . First describe Fuller Albright 1944 , IOP uncommon condition estimate annual incidence 0.4 case per 100,0003 . IOP predominantly affect Caucasians , generally present mid-30s one low trauma fracture . In course NIH-funded study premenopausal woman IOP ( R01 AR49896 , IRB AAAA9245 ) , investigator show woman IOP low areal bone mineral density ( aBMD ) spine , hip forearm compare normal woman . Additionally , use noninvasive high resolution image central peripheral skeleton detail analysis transiliac crest bone biopsy , investigator identify several distinctive consistent feature bone quality premenopausal woman IOP : thin cortex , low trabecular volumetric bone mineral density ( vBMD ) , few trabecular plate , few longer trabecular rod , decrease connectivity rod plate , low mineralization density lower estimate stiffness cancellous bone . Bone remodel biochemical index mineral metabolism differ IOP subject control . Although every woman IOP require pharmacologic intervention , many sustain multiple low-trauma fracture extremely low bone mineral density ( BMD ) . There currently FDA-approved therapy IOP premenopausal woman , therefore safe effective therapy urgently need . Bisphosphonates one therapeutic option associate gain BMD primarily due reduction remodel space increase mineralization bone rather improvement microarchitecture , important consideration microarchitectural deficit consistent feature IOP premenopausal woman , remodel activity commonly normal low . Furthermore , potential teratogenic effect limit safety bisphosphonates premenopausal woman . However , anabolic therapy human recombinant parathyroid hormone 1-34 , hPTH ( 1-34 ) teriparatide ( TPTD ) , term use interchangeably proposal , show improve bone mass microarchitecture postmenopausal woman approve men primary idiopathic osteoporosis , well men , premenopausal postmenopausal woman glucocorticoid-induced osteoporosis . TPTD , hand , increase bone formation BMD , improve microarchitecture strength . Moreover , TPTD show increase BMD men IOP , premenopausal woman glucocorticoid-induced osteoporosis ( GIOP ) prevent bone loss premenopausal woman nafarelin-induced acute estrogen deficiency . Although study evaluate TPTD estrogen-replete premenopausal woman IOP , data study hPTH ( 1-34 ) postmenopausal woman estrogen relevant proposal . These study find increase aBMD LS less magnitude hip , well major reduction vertebral fracture . Also important , BMD remain stable postmenopausal woman estrogen follow two year TPTD discontinuation . Lane et al . report similar result postmenopausal woman GIOP estrogen . These two study suggest estrogen-replete premenopausal woman IOP , increase bone mass result TPTD sustain course therapy complete . The major objective protocol therapeutic one , namely establish safety efficacy TPTD premenopausal woman IOP phase 2 clinical trial . The investigator hypothesize anabolic therapy teriparatide improve areal vBMD premenopausal woman IOP . The investigator also hypothesize teriparatide restore abnormal microarchitecture toward normal improve aspect bone quality premenopausal woman IOP . The primary aim research study establish efficacy safety 6 month teriparatide versus placebo premenopausal woman IOP . The secondary aim determine extent 12 24 month teriparatide improves areal volumetric BMD , bone microarchitecture stiffness compare baseline measure premenopausal woman IOP . This study high impact clinical practice pertains management premenopausal woman IOP . This study exploratory support new label claim Forteo premenopausal patient population .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Premenopausal woman , aged 2045 , regular menses historical biochemical secondary cause osteoporosis . Documented adult fracture judge lowtrauma . Must willing use effective contraception throughout period study drug administration . Inclusion Criteria vary slightly base age category : Premenopausal woman age 2035 year must least one major osteoporotic fracture ( exclude fracture finger , toe face ) low Bone Mineral Density ( BMD ) . Premenopausal woman age 35 year history fracture and/or low BMD . History condition increase risk osteosarcoma Early follicular phase serum Disorders mineral metabolism Suspicion osteomalacia Vitamin D deficiency Pregnancy lactation within past 12 month Prolonged amenorrhea ( &gt; 6 month ) reproductive year ( except pregnancy lactation ) Prior eat disorder Malignancy , except cure basal squamous cell skin carcinoma Endocrinopathy : new onset untreated hyperthyroidism , hypothyroidism , Cushing 's syndrome , prolactinoma Renal insufficiency Liver disease Intestinal disorder History/current glucocorticoid ( GCs ) , anticonvulsant , anticoagulant , methotrexate , depot progesterone , Gonadotrophinreleasing hormone ( GnRH ) agonists Oral glucocorticoid use ( subject exclude use dose equivalent less prednisone 5 mg &lt; 3 month ) . Current anticoagulant use low molecular weight Depo Provera use ( subject exclude used age &gt; 20 , &gt; 5 year ago ) Drugs osteoporosis ( raloxifene , bisphosphonates , denosumab , calcitonin , TPTD ) . Subjects discontinue medication eligible 3 month stop raloxifene calcitonin , 12 month stop alendronate , risedronate , ibandronate , pamidronate 18 month stop denosumab . Subjects prior use zoledronate may eligible receive one dose &gt; 4 year ago . Total bisphosphonate exposure must &lt; 1 year . Subjects take TPTD past eligible unless use &lt; 3 month , &gt; 2 year ago .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>premenopausal</keyword>
	<keyword>forteo</keyword>
	<keyword>idiopathic</keyword>
	<keyword>Idiopathic Osteoporosis Premenopausal Women</keyword>
</DOC>